Scarica l'app Stockscreener
23.99
0.29%
0.07
Dopo l'orario di chiusura:
23.55
-0.44
-1.83%
Precedente Chiudi:
$23.92
Aprire:
$23.98
Volume 24 ore:
1.43M
Relative Volume:
0.99
Capitalizzazione di mercato:
$2.11B
Reddito:
-
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-11.65
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
-0.79%
1M Prestazione:
-12.38%
6M Prestazione:
-33.44%
1 anno Prestazione:
+78.36%
Intervallo 1D:
$23.29
$24.25
Intervallo di 1 settimana:
$23.26
$25.02
Portata 52W:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
23.99 | 2.11B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics (MLYS) affiliate lists multi-date sales and a 3,542-share exercise - Stock Titan
Mineralys Therapeutics Reports Significant Reductions in Heart Failure Risk Biomarkers Associated with Lorundrostat in Proteomic Analysis - Quiver Quantitative
Blood protein shifts hint at heart failure pathways for lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) CMO sells 8,519 shares after option exercises - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) files Rule 144 disclosing 6,349‑share cashless exercise - Stock Titan
Akin, an Elite Global Law Firm - Akin
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Insider Monkey
Transcript : Mineralys Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 02 - marketscreener.com
Mineralys Therapeutics Announces Royalty Repurchase, $500 Million Debt Facility, and $150 Million Equity Offering - Global Legal Chronicle
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
5 Best AI Driven Biotech Stocks to Invest In - Insider Monkey
MLYS: Lorundrostat advances toward launch with strong clinical data, strategic deals, and broad payer support - TradingView
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Biopharma Mineralys joins Goldman Sachs health-care talks in Miami - Stock Titan
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - The Manila Times
Mineralys Therapeutics to Present Late-Breaking Data on - GlobeNewswire
Latham Advises Mineralys Therapeutics in Unique Three-Pronged Transaction — Royalty Repurchase, Debt Financing, and Equity Offering — Totaling Up to US$950 Million - Legal Desire Media and Insights
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Yahoo Finance
Mineralys Therapeutics Stock In Shambles: Down -25% With 6-Day Losing Streak - Trefis
Mineralys Therapeutics Stock Plummets 25% With 6-Day Losing Streak - Trefis
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Insider Monkey
Mineralys Therapeutics prices $150M stock offering - MSN
Latham Advises Mineralys Therapeutics in Unique Three-Pronged - Latham & Watkins LLP
Mineralys pays up to $300 million to clear lorundrostat royalties - The Pharma Letter
MLYS Stock Sees 17.1% Decline Amid Market Movements - GuruFocus
Mineralys announces $150 million equity offering and financing - TipRanks
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Moomoo
Mineralys Stock Drops Before Open After $150 Million Sale Tests Blood-Pressure Drug Bet - Bez Kabli
Mineralys raises $750M through debt, equity and royalty deal By Investing.com - Investing.com India
Why Mineralys Therapeutics Stock Is Sliding Today - TipRanks
Mineralys prices $150 million stock offering at $26.50 per share By Investing.com - Investing.com South Africa
BioPharma Credit provides up to $150m loan to Mineralys By Investing.com - Investing.com Australia
BioPharma Credit provides up to $150m loan to Mineralys - Investing.com
Mineralys Secures Lorundrostat Rights and Major Financing Facility - TipRanks
Mineralys Therapeutics Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
Mineralys Therapeutics Announces Pricing Of $150 Million Underwritten Offering Of Common Stock - TradingView
Mineralys Therapeutics Announces Repurchase Of Royalty Obligations In Tanabe License Agreement And Concurrent Financing - TradingView
Mineralys prices $150 million stock offering at $26.50 per share - Investing.com UK
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Mineralys raises $750M through debt, equity and royalty deal - Investing.com
Mineralys Locks In Royalty-Free Lorundrostat Rights With $200M Payment, Secures $500M Term Loan - TradingView
Mineralys Therapeutics Prices Underwritten Offering of 5.6 Million Shares at $26.50 Per Share, Expected to Raise $150 Million - Quiver Quantitative
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing - The Manila Times
Mineralys (NASDAQ: MLYS) gets $500M loan, ends lorundrostat royalty payments - Stock Titan
Mineralys Therapeutics, Inc. Enters into Senior Secured Term Loan Agreement for Up to $500 Million - marketscreener.com
Jefferies reiterates Hold on Mineralys stock amid M&A speculation By Investing.com - Investing.com Australia
Velan Capital Cuts Mineralys Therapeutics Stake by 140000 Shares - asatunews.co.id
Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular ProtectionSlideshow (NASDAQ:MLYS) 2026-06-01 - Seeking Alpha
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mineralys Therapeutics Inc Azioni (MLYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Jun 10 '26 |
Option Exercise |
16.00 |
2,170 |
34,720 |
65,613 |
| Rodman David Malcom | Chief Medical Officer |
Jun 12 '26 |
Option Exercise |
1.08 |
6,349 |
6,857 |
69,792 |
| Rodman David Malcom | Chief Medical Officer |
Jun 12 '26 |
Sale |
23.93 |
6,349 |
151,901 |
63,443 |
| Rodman David Malcom | Chief Medical Officer |
Jun 10 '26 |
Sale |
25.00 |
2,170 |
54,250 |
63,443 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):